ADEPT DBS
Research type
Research Study
Full title
A multi-centre, prospective study exploring the use of neuronal signals to identify the ideal location to implant and apply Deep Brain Stimulation (DBS) in the Treatment of Parkinson’s Disease.
IRAS ID
311721
Contact name
Tom Foltynie
Contact email
Sponsor organisation
The Bionics Institute of Australia
Clinicaltrials.gov Identifier
ANZCTR trial registry: , ACTRN12621001323819; Universal Trial Number: , U1111-1268-5579
Duration of Study in the UK
2 years, 5 months, 31 days
Research summary
Deep Brain Stimulation (DBS) is a type of treatment that can improve the symptoms and quality of life of people with Parkinson’s disease (PD). During DBS surgery, a thin metal wire (lead) that contains a number of electrodes is implanted into the brain. After surgery, the doctor ‘programs’ the DBS system to determine the best settings for each patient. In particular, the doctor needs to determine which electrodes on the lead should be chosen to deliver DBS. How well someone responds to DBS is heavily dependent on how accurately the DBS lead is placed in the brain and the location the doctor selects to deliver DBS.
The study ADEPT DBS investigates a new electrical signal, evoked resonant neural activity (ERNA), which is recorded from the DBS leads in the brain during surgery. The study aims to assess whether ERNA can be safely and reliably recorded from the DBS leads of people with PD. The study also investigates information on where to place the DBS lead during surgery and which electrodes to select to deliver DBS. Participants enrolled in the study will be required to attend three to five study visits to record baseline data, collect questionnaires and assess the symptoms of PD. The study visits will take place over a 16-month period, from prior to the DBS surgery, to 12 months after surgery.
People with PD who are planning to have DBS surgery as part of their usual clinical care at the National Hospital for Neurology and Neurosurgery (London) and John Radcliffe Hospital (Oxford) will be eligible to participate in the study.
The study is sponsored by the Bionics Institute of Australia, a not-for-profit medical research institute in Melbourne, Australia. In the United Kingdom, we aim to recruit a minimum of 30 participants across the two hospitals over 3 years.REC name
West of Scotland REC 4
REC reference
22/WS/0095
Date of REC Opinion
18 Aug 2022
REC opinion
Further Information Favourable Opinion